Generation Bio Co. (NASDAQ:GBIO) Given Consensus Rating of “Moderate Buy” by Brokerages

Generation Bio Co. (NASDAQ:GBIO) has been given an average rating of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $9.05.

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Generation Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Wednesday, August 16th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 target price on shares of Generation Bio in a research report on Thursday, August 3rd. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Generation Bio in a research report on Thursday, August 3rd.

Hedge Funds Weigh In On Generation Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC boosted its position in Generation Bio by 0.4% in the first quarter. FMR LLC now owns 8,949,863 shares of the company’s stock valued at $38,484,000 after buying an additional 36,532 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Generation Bio by 1.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 8,931,613 shares of the company’s stock valued at $58,591,000 after buying an additional 167,922 shares in the last quarter. BlackRock Inc. boosted its position in Generation Bio by 3.3% in the third quarter. BlackRock Inc. now owns 3,616,045 shares of the company’s stock valued at $19,202,000 after buying an additional 114,082 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Generation Bio by 2.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,577,755 shares of the company’s stock valued at $14,061,000 after buying an additional 95,138 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Generation Bio by 0.4% in the third quarter. Vanguard Group Inc. now owns 2,218,522 shares of the company’s stock worth $11,780,000 after acquiring an additional 8,213 shares during the last quarter. 95.81% of the stock is currently owned by institutional investors and hedge funds.

Generation Bio Stock Performance

NASDAQ:GBIO opened at $4.62 on Friday. The firm’s 50-day moving average is $4.98 and its 200-day moving average is $4.64. Generation Bio has a 52-week low of $3.15 and a 52-week high of $7.35. The company has a market cap of $304.59 million, a price-to-earnings ratio of -2.22 and a beta of 2.22.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $0.88 million for the quarter, compared to the consensus estimate of $7.50 million. Equities analysts predict that Generation Bio will post -2.05 EPS for the current year.

About Generation Bio

Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.